drugset / Trial / NCT02171572

Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects

NCT02171572

Phase 1 Completed 28 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of the current study is to investigate safety, tolerability and, pharmacokinetics of dabigatran etexilate following oral administration of single and multiple oral doses (110mg, 150 mg b.i.d., 7 days) in healthy Chinese subjects.

Timeline

Start
2009-10
Primary completion
2009-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 110 mg Oral
Subject Dabigatran etexilate Unknown 150 mg Oral

Indications

No indication recorded.